Background: Rearranged during transfection (RET) gene fusions are detected in 10–20% of thyroid cancer patients. Recently, RET fusion-positive metastatic thyroid cancers have attracted much attention owing to the FDA approval of two highly selective anti-RET tyrosine kinase inhibitors, namely, selpercatinib, and pralsetinib. Areas covered: This review summarizes the available evidence on the biological and predictive role of RET gene fusions in thyroid carcinoma patients and the latest screening assays currently used to detect these genomic alterations in histological and cytological specimens. Expert opinion: Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.

Nacchio, M., Pisapia, P., Pepe, F., Russo, G., Vigliar, E., Porcelli, T., et al. (2022). Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 17(2), 167-178 [10.1080/17446651.2022.2060819].

Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions

Pagni F.;
2022

Abstract

Background: Rearranged during transfection (RET) gene fusions are detected in 10–20% of thyroid cancer patients. Recently, RET fusion-positive metastatic thyroid cancers have attracted much attention owing to the FDA approval of two highly selective anti-RET tyrosine kinase inhibitors, namely, selpercatinib, and pralsetinib. Areas covered: This review summarizes the available evidence on the biological and predictive role of RET gene fusions in thyroid carcinoma patients and the latest screening assays currently used to detect these genomic alterations in histological and cytological specimens. Expert opinion: Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.
Articolo in rivista - Articolo scientifico
molecular pathology; pralsetinib; RET fusion; selpercatinib; Thyroid cancer;
English
167
178
12
Nacchio, M., Pisapia, P., Pepe, F., Russo, G., Vigliar, E., Porcelli, T., et al. (2022). Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 17(2), 167-178 [10.1080/17446651.2022.2060819].
Nacchio, M; Pisapia, P; Pepe, F; Russo, G; Vigliar, E; Porcelli, T; Luongo, C; Iaccarino, A; Pagni, F; Salvatore, D; Troncone, G; Malapelle, U; Bellevicine, C
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/367928
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact